Announcements & Circulars-Alphamab Oncology

English 中文简体中文繁体

English 中文简体中文繁体

Investors

Information Disclosure

Listing Documents

Financial Reports

Announcements & Circulars

Company Presentation

Corporate Governance

Stock Information

Corporate Communications

Email Subscription

Announcements & Circulars

The announcement begins in December 2019

VOLUNTARY ANNOUNCEMENT – RESEARCH UPDATES OF JSKN016 FOR PRESENTATION AT 2026 ASCO ANNUAL MEETING 2026-06-02
VOLUNTARY ANNOUNCEMENT – RESULTS OF PHASE III CLINICAL STUDY OF ANBENITAMAB (KN026) FOR NEOADJUVANT TREATMENT OF BC WERE PRESENTED AT LBA ORAL PRESENTATION SESSION OF 2026 ASCO ANNUAL MEETING 2026-06-01
INSIDE INFORMATION ANNOUNCEMENT – 恩尼妥® (ANBENITAMAB INJECTION) OBTAINED MARKETING APPROVAL FROM THE NMPA 2026-05-29
Next Day Disclosure Return 2026-05-21
FORM OF PROXY FOR USE AT THE ANNUAL GENERAL MEETING TO BE HELD ON FRIDAY, JUNE 12, 2026 2026-05-20
NOTICE OF ANNUAL GENERAL MEETING 2026-05-20
(1) PROPOSED GRANTING OF GENERAL MANDATES TO REPURCHASE SHARES AND TO ISSUE NEW SHARES (INCLUDING RESELL OR TRANSFER TREASURY SHARES); (2) PROPOSED RE-ELECTION OF THE RETIRING DIRECTORS; (3) PROPOSED RE-APPOINTMENT OF AUDITORS; AND (4) NOTICE OF ANNUAL GENERAL MEETING 2026-05-20
VOLUNTARY ANNOUNCEMENT – FIRST PATIENT DOSED IN A PHASE II CLINICAL STUDY OF JSKN033 AS FIRST-LINE TREATMENT OF ADVANCED CERVICAL CANCER 2026-05-13
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 April 2026 2026-05-07
GRANT OF AWARD SHARES UNDER THE RESTRICTED SHARE AWARD SCHEME 2026-04-23